| Period | JAGX | SPY | Delta |
|---|---|---|---|
| 3M | -86.0% | +11.4% | -97.3% |
| 6M | -93.6% | +8.2% | -101.8% |
| 1Y | -98.0% | +22.9% | -120.8% |
No financial data available for JAGX.
Company may not file with SEC or CIK is unresolved.
Jaguar Health reported Q1 2026 net revenue of $20.3 million, up 816% year-over-year, driven by $16 million licensing deal for Mytesi and Canalevia-CA1 U.S. commercial rights to Future Pak
“This decision aligns with Jaguar's strategic focus on advancing the development of its powder-for-oral-solution formulation of crofelemer for rare-disease indications related to intestinal failure in humans.”
No Form 4 transactions on record.
Informational purposes only, not investment advice.